Post-transplant diagnosis of atypical hemolytic uremic syndrome due to a pathogenic mutation in complement factor I in a patient with IgA nephropathy
Clinical Nephrology – Case Studies · 01.01.2026 · 14 (01) · 93-98
DOI: 10.5414/cncs112070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology – Case Studies, erschienen am 01.01.2026. Verfasst von Asli Karsli Demirsoy und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated thrombotic microangiopathy (TMA) that may be triggered by kidney transplantation (KT) in genetically predisposed individuals. Its occurrence in patients with IgA nephropathy is uncommon and diagnostically challenging. We report a 28-year-old male with progressive IgA nephropathy who underwent pre-emptive living-donor KT. In the immediate post-transplant period, he developed thrombocytopenia, microangiopathic hemolytic anemia, elevated lactate dehydrogenase, low haptoglobin, and decreased C3 levels, consistent with TMA. ADAMTS13 activity was normal, excluding thrombotic thrombocytopenic purpura. Despite calcineurin inhibitor withdrawal and plasma exchange, hematologic and renal recovery did not occur, and dialysis was initiated. Treatment with eculizumab resulted in rapid hematologic improvement and progressive graft recovery, allowing dialysis discontinuation. Genetic testing revealed a pathogenic complement factor I mutation (p.R474X). At the 3-year follow-up, graft function remained stable without recurrence. This case highlights kidney transplantation as a trigger for complement-mediated TMA in genetically susceptible individuals and underscores the importance of early complement inhibition. Complement genetic testing may be considered in selected transplant candidates with aggressive IgA nephropathy phenotypes. Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated thrombotic microangiopathy (TMA) that may be triggered by kidney transplantation (KT) in genetically predisposed individuals. Its occurrence in patients with IgA nephropathy is uncommon and diagnostically challenging. We report a 28-year-old male with progressive IgA nephropathy who underwent pre-emptive living-donor KT. In the immediate post-transplant period, he developed thrombocytopenia, microangiopathic hemolytic anemia, elevated lactate dehydrogenase, low haptoglobin, and decreased C3 levels, consistent with TMA. ADAMTS13 activity was normal, excluding thrombotic thrombocytopenic purpura. Despite calcineurin inhibitor withdrawal and plasma exchange, hematologic and renal recovery did not occur, and dialysis was initiated. Treatment with eculizumab resulted in rapid hematologic improvement and progressive graft recovery, allowing dialysis discontinuation. Genetic testing revealed a pathogenic complement factor I mutation (p.R474X). At the 3-year follow-up, graft function remained stable without recurrence. This case highlights kidney transplantation as a trigger for complement-mediated TMA in genetically susceptible individuals and underscores the importance of early complement inhibition. Complement genetic testing may be considered in selected transplant candidates with aggressive IgA nephropathy phenotypes. Author Details Authors Asli Karsli DemirsoyHarun CobanDilek Barutcu AtasMurat TugcuIzzet Hakki ArikanEbru AsiciogluSerhan TuglularArzu Velioglu Departments Marmara University, School of Medicine, Department of Nephrology, Istanbul, Turkey Address Arzu Velioğlu, MD, Marmara University Pendik Teaching and Training Hospital, Ust-Kaynarca/Pendik, Istanbul, TurkeyEmail: [email protected] Log in for Subscribers Enter your username and password here in order to log in on the website: Username: Password: Forgot your password? Citation Asli Karsli Demirsoy, Harun Coban, Dilek Barutcu Atas, Murat Tugcu, Izzet Hakki Arikan, Ebru Asicioglu, Serhan Tuglular, and Arzu Velioglu. Post-transplant diagnosis of atypical hemolytic uremic syndrome due to a pathogenic mutation in complement factor I in a patient with IgA nephropathy. Clinical Nephrology - Case Studies. 2026; 14: 93-98. doi: 10.5414/CNCS112070.
Zitieren
APA
Demirsoy, A. K., Coban, H., Atas, D. B., Tugcu, M., Arikan, I. H., Asicioglu, E., Tuglular, S., & Velioglu, A. (2026). Post-transplant diagnosis of atypical hemolytic uremic syndrome due to a pathogenic mutation in complement factor I in a patient with IgA nephropathy. Clinical Nephrology – Case Studies, 14(01), 93-98. https://doi.org/10.5414/cncs112070
Vancouver
Demirsoy AK, Coban H, Atas DB, Tugcu M, Arikan IH, Asicioglu E, et al. Post-transplant diagnosis of atypical hemolytic uremic syndrome due to a pathogenic mutation in complement factor I in a patient with IgA nephropathy. Clinical Nephrology – Case Studies. 2026;14(01):93-98. doi:10.5414/cncs112070
BibTeX
@article{Demirsoy2026,
author = {Demirsoy, Asli Karsli and Coban, Harun and Atas, Dilek Barutcu and Tugcu, Murat and Arikan, Izzet Hakki and Asicioglu, Ebru and Tuglular, Serhan and Velioglu, Arzu},
title = {Post-transplant diagnosis of atypical hemolytic uremic syndrome due to a pathogenic mutation in complement factor I in a patient with IgA nephropathy},
journal = {Clinical Nephrology – Case Studies},
year = {2026},
volume = {14},
number = {01},
pages = {93--98},
doi = {10.5414/cncs112070}
}
EUVIMED